DNA-PK Inhibitors
DNA-dependent protein kinase (DNA-PK) is a critical serine/threonine kinase that plays a fundamental role in the detection and repair of DNA double-strand breaks (DSBs) through the non-homologous end joining (NHEJ) pathway. The DNA-PK complex consists of a large catalytic subunit (DNA-PKcs) and a heterodimeric Ku70/Ku80 regulatory component that binds to DNA ends. Upon recruitment to a DSB, DNA-PKcs undergoes autophosphorylation and phosphorylates other repair factors, such as Artemis and XRCC4, to facilitate the ligation of broken DNA strands. Because DNA-PK is essential for maintaining genomic stability, its inhibition is a potent strategy for sensitizing cancer cells to DNA-damaging agents, including ionizing radiation and certain chemotherapies like bleomycin or topoisomerase inhibitors. High levels of DNA-PK expression have been associated with resistance to therapy and poor prognosis in various malignancies, such as prostate, pancreatic, and lung cancers.
The development of DNA-PK inhibitors has moved from early research tools like wortmannin and LY294002, which were relatively non-specific, to highly potent and selective ATP-competitive small molecules. Several of these agents are currently in clinical trials. For instance, peposertib (M3814) and nedisertib (M3541) are being evaluated in combination with radiotherapy and chemotherapy to enhance anti-tumor responses. These inhibitors are primarily classified as small-molecule ATP-competitive inhibitors of the DNA-PKcs subunit. A significant challenge in the clinical application of DNA-PK inhibitors is the potential for increased toxicity in normal tissues, as NHEJ is a ubiquitous repair mechanism.
Therefore, careful dose escalation and the use of targeted delivery or localized radiation are critical components of clinical trial design. Another area of intense research is the use of DNA-PK inhibitors in the context of synthetic lethality, particularly in tumors with defects in alternative repair pathways like homologous recombination (HR). There is also emerging evidence that DNA-PK inhibition can modulate the tumor immune microenvironment by promoting the accumulation of cytosolic DNA, which activates the cGAS-STING pathway and triggers an interferon response. This has led to interest in combining DNA-PK inhibitors with immune checkpoint blockers. Furthermore, the structural biology of the DNA-PK complex has recently been elucidated using cryo-electron microscopy, providing new insights for the design of even more selective and potent inhibitors.
As clinical data continues to emerge, the role of DNA-PK inhibitors as powerful adjuncts to standard-of-care cancer treatments is becoming increasingly clear, offering a promising avenue for overcoming treatment resistance and improving patient outcomes in the oncology setting.
